A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell
activity, thus enhancing immune response and has potential to treat various types of tumors.
In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the
treatment of patients with metastatic triple-negative breast cancer will be evaluated.